Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Anixa Biosciences Inc

Get SEC filing alerts via email and in your feed for Anixa Biosciences Inc

ANIX

Anixa Biosciences Inc

About Anixa Biosciences Inc

Anixa Biosciences, Inc. is a biotechnology company focused on developing novel immunotherapies and vaccines targeting unmet needs in oncology. Its core programs include a chimeric endocrine receptor CAR-T cell therapy for ovarian cancer and vaccines for triple-negative breast cancer and ovarian cancer, licensed from leading research institutions. Anixa’s business model centers on advancing clinical trials and partnering with pharmaceutical companies for manufacturing, marketing, and commercialization of its cancer therapies.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Anixa Biosciences Inc

1
1
Anixa Biosciences Inc Anixa Biosciences Reports No Revenue in Q2 Fiscal 2026, Operating Expenses Decrease

Via official filing (AI summary) | 5 days ago | 0 comments

2
1
Anixa Biosciences Inc Anixa Biosciences Reports No Revenue, Decreases Net Loss to $2.585 Million

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Anixa Biosciences Inc Anixa Biosciences Reports No Revenue for Fiscal Year Ending October 31, 2025

Via official filing (AI summary) | 5 months ago | 0 comments

4
1
Anixa Biosciences Inc Anixa Biosciences Reports No Revenue, Decreases Net Loss in Third Quarter 2025

Via official filing (AI summary) | 9 months ago | 0 comments

5
1
Anixa Biosciences Inc Anixa Biosciences Reports $2.8 Million Net Loss in Q2 Fiscal 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Anixa Biosciences Inc Anixa Biosciences Reports $3.2 Million Net Loss, Focuses on Cancer Therapy Development

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Anixa Biosciences Inc Anixa Biosciences Reports Increased Expenses and Net Loss in Q3 2024, Focuses on Research and Development

Via official filing (AI summary) | almost 2 years ago | 0 comments